293 related articles for article (PubMed ID: 28319647)
1. Cancer-Specific, Intracellular, Reductive Activation of Anticancer Pt
Reshetnikov V; Daum S; Mokhir A
Chemistry; 2017 Apr; 23(24):5678-5681. PubMed ID: 28319647
[TBL] [Abstract][Full Text] [Related]
2. Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis.
Ma L; Ma R; Wang Z; Yiu SM; Zhu G
Chem Commun (Camb); 2016 Sep; 52(71):10735-8. PubMed ID: 27506281
[TBL] [Abstract][Full Text] [Related]
3. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
4. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs.
Ravera M; Gabano E; Zanellato I; Fregonese F; Pelosi G; Platts JA; Osella D
Dalton Trans; 2016 Mar; 45(12):5300-9. PubMed ID: 26903367
[TBL] [Abstract][Full Text] [Related]
6. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.
Wong DY; Yeo CH; Ang WH
Angew Chem Int Ed Engl; 2014 Jun; 53(26):6752-6. PubMed ID: 24844571
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, characterization, and cytotoxicity of dinuclear platinum-bisphosphonate complexes to be used as prodrugs in the local treatment of bone tumours.
Margiotta N; Ostuni R; Gandin V; Marzano C; Piccinonna S; Natile G
Dalton Trans; 2009 Dec; (48):10904-13. PubMed ID: 20023921
[TBL] [Abstract][Full Text] [Related]
8. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
9. What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt E; Gibson D
J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
[TBL] [Abstract][Full Text] [Related]
10. 4-Azidobenzyl ferrocenylcarbamate as an anticancer prodrug activated under reductive conditions.
Kinski E; Marzenell P; Hofer W; Hagen H; Raskatov JA; Knaup KX; Zolnhofer EM; Meyer K; Mokhir A
J Inorg Biochem; 2016 Jul; 160():218-24. PubMed ID: 26970945
[TBL] [Abstract][Full Text] [Related]
11. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
[TBL] [Abstract][Full Text] [Related]
12. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
13. Aminoferrocene-based prodrugs activated by reactive oxygen species.
Hagen H; Marzenell P; Jentzsch E; Wenz F; Veldwijk MR; Mokhir A
J Med Chem; 2012 Jan; 55(2):924-34. PubMed ID: 22185340
[TBL] [Abstract][Full Text] [Related]
14. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands.
Deng Z; Zhu G
Curr Opin Chem Biol; 2023 Jun; 74():102303. PubMed ID: 37075513
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cancer cell killing of a Pt(IV) prodrug promoted by outer-sphere coordination with polyethyleneimines.
Garaikoetxea Arguinzoniz A; Gómez Blanco N; Ansorena Legarra P; Mareque-Rivas JC
Dalton Trans; 2015 Apr; 44(16):7135-8. PubMed ID: 25812853
[TBL] [Abstract][Full Text] [Related]
16. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.
Thiabaud G; McCall R; He G; Arambula JF; Siddik ZH; Sessler JL
Angew Chem Int Ed Engl; 2016 Oct; 55(41):12626-31. PubMed ID: 27377046
[TBL] [Abstract][Full Text] [Related]
17. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
18. Tuning the structure of aminoferrocene-based anticancer prodrugs to prevent their aggregation in aqueous solution.
Daum S; Babiy S; Konovalova H; Hofer W; Shtemenko A; Shtemenko N; Janko C; Alexiou C; Mokhir A
J Inorg Biochem; 2018 Jan; 178():9-17. PubMed ID: 29028541
[TBL] [Abstract][Full Text] [Related]
19. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
Huo S; Shen S; Liu D; Shi T
J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations.
Song Y; Suntharalingam K; Yeung JS; Royzen M; Lippard SJ
Bioconjug Chem; 2013 Oct; 24(10):1733-40. PubMed ID: 23957697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
